Adastra Holdings (CSE:XTRX) Ltd announced that its Adastra Labs Inc subsidiary has received its flower sales license amendment from Health Canada effective December 17, 2021.
The Langley, British Columbia-based company said that the flower sales license will allow Adastra Labs to sell dried cannabis flower products provincially and territorially in Canada through authorized distributors and retailers.
"Receiving our flower sales license is a significant milestone and provides Adastra with an additional pathway to pursue higher-margin revenue growth within the Canadian cannabis market," said Donald Dinsmore, chief operating officer in a statement.
He added: "With the ability to be a direct supplier, we are now even better positioned to leverage the strong awareness and existing shelf space of our popular Phyto Extractions brand, as well as our national inside sales force, by offering an expanded portfolio of other products targeted at the cost-conscious and the premium craft consumers that will include pre-rolls and dried flower offerings."
READ: Adastra Holdings reports significant revenue bump in 3Q, targeting $5 million in monthly sales by the end of 2022
Dried cannabis flower is in high demand from provincial distributors and medical clients. According to Statistics Canada, dried flower sales accounted for nearly three-quarters of legal recreational cannabis sales in the first half of 2021, worth over $1.3 billion in sales.
Michael Forbes, CEO of Adastra, commented, "Adastra is in a great position to maximize profits through the continued reduction in biomass costs and the little need for capital expenditure. I am particularly excited about the upcoming launch of infused pre-rolls, as they are the fastest-growing segment in the flower category.
Adastra is a leading manufacturer and supplier of innovative ethnobotanical and cannabis science products designed for the adult-use and medical markets and forward-looking therapeutic applications.
Contact Ritika at ritika@proactiveinvestors.com